Remove Dermatitis Remove Safety Remove Sustainability
article thumbnail

New Phase 3 Data on Long-Term Efficacy of Upadacitinib in Atopic Dermatitis Presented at EADV

Dermatology Times

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

article thumbnail

Sanofi’s OX40-ligand Blocker Produces High Durable Response Rates in AD With Quarterly Dosing

The Dermatology Digest

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Breaking News from Maui Derm 2024: Nemolizumab Improves Lesions, Relieves Itch in AD

The Dermatology Digest

Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis.

article thumbnail

Skincare Trends: Clean Beauty and Sustainability

The Dermatology Digest

Patricia Farris discusses skincare industry trends, including consumer demand for “clean beauty,” sustainability, and resources for consumer and dermatologist ingredient education. So we just don’t have the standardization of what is being eliminated and no consensus as to what should be eliminated based on safety studies.

article thumbnail

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

The Dermatology Digest

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

article thumbnail

How can I tell if a product will cause acne? Episode 155

The Beauty Brains

According to Fisher’s Contact Dermatitis, acne can result from topical application of cosmetic products via two mechanisms. The second is It MIGHT make sense from a sustainability point of view – you make the product more concentrated so you get more uses per bottle which reduces packaging waste.